A Phase 1 interventional study of Cohort 1 (JP-1366 A mg) and Cohort 2 (JP-1366 B mg) in Anti-Ulcer Agents, sponsored by Jeil Pharmaceutical Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to male participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-04-22.
Sponsored by Jeil Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Clinical trial to investigate the safety, tolerability and pharmacokinetics and pharmacodynamics of JP-1366 oral administration in healthy male subjects
359 studies on the registry are indexed under Ulcer; 60 are open to participants now.
This study's enrollment of 115 is above the median of 65 across 291 interventional studies indexed under Ulcer.
Browse Ulcer studies →Jeil Pharmaceutical Co., Ltd. is the lead sponsor of 38 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single-ascending cohort 1
Drug: Cohort 1 (JP-1366 A mg)
Single-ascending cohort 2
Drug: Cohort 2 (JP-1366 B mg)
Single-ascending cohort 3
Drug: Cohort 3 (JP-1366 C mg)
Single-ascending cohort 4
Drug: Cohort 4 (JP-1366 D mg)
Single-ascending cohort 5
Drug: Cohort 5 (JP-1366 E mg)
Multiple-ascending cohort 1
Drug: Cohort 6 (JP-1366 F mg)
Multiple-ascending cohort 2
Drug: Cohort 7 (JP-1366 G mg)
Multiple-ascending cohort 3
Drug: Cohort 8 (JP-1366 H mg)
Multiple-ascending cohort 4
Drug: Cohort 9 (JP-1366 I mg)
Drug: JP-1366 A mg or JP-1366 Placebo or Esomeprazole 40 mg
Also known as: SAD
Drug: JP-1366 B mg or JP-1366 Placebo or Esomeprazole 40 mg
Also known as: SAD
Drug: JP-1366 C mg or JP-1366 Placebo or Esomeprazole 40 mg
Also known as: SAD
Drug: JP-1366 D mg or JP-1366 Placebo or Esomeprazole 40 mg
Also known as: SAD
Drug: JP-1366 E mg or JP-1366 Placebo or Esomeprazole 40 mg
Also known as: SAD
Drug: JP-1366 F mg or JP-1366 Placebo or Esomeprazole 40 mg
Also known as: MAD
Drug: JP-1366 G mg or JP-1366 Placebo or Esomeprazole 40 mg
Also known as: MAD
Drug: JP-1366 H mg or JP-1366 Placebo or Esomeprazole 40 mg
Also known as: MAD
Drug: JP-1366 I mg or JP-1366 Placebo or Esomeprazole 40 mg
Also known as: MAD
Cmax
SAD endpoint
Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hours post-dose
AUClast
SAD endpoint
Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hours post-dose
AUCinf
SAD endpoint
Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hours post-dose
tmax
SAD endpoint
Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hours post-dose
t1/2
SAD endpoint
Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hours post-dose
Cmax,ss
MAD endpoint
Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24h post-dose, Day 3-6, pre-dose, Day 7 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hour post-dose
Cmin,ss
MAD endpoint
Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24h post-dose, Day 3-6, pre-dose, Day 7 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hour post-dose
Cav,ss
MAD endpoint
Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24h post-dose, Day 3-6, pre-dose, Day 7 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hour post-dose
AUCτ
MAD endpoint
Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24h post-dose, Day 3-6, pre-dose, Day 7 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hour post-dose
tmax,ss
MAD endpoint
Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24h post-dose, Day 3-6, pre-dose, Day 7 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hour post-dose
t1/2
MAD endpoint
Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24h post-dose, Day 3-6, pre-dose, Day 7 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hour post-dose
Percentage of total time that the intragastric pH was above 4
SAD
Time frame: 0-24 hours(Day -1), 0-24 hours(Day 1)
Percentage of total time that the intragastric pH was above 4
MAD
Time frame: 0-24 hours (Day -1), 0-24 hours (Day 1), 0-24 hours (Day 7)
Serum gastrin concentration
SAD
Time frame: Pre-dose, 2, 4, 6, 8, 12h post-dose, Day 1 pre-dose, 2, 4, 6, 8, 12, 24, 48h post-dose
Serum gastrin concentration
MAD
Time frame: Pre-dose, 2, 4, 6, 8, 12h post-dose, Day 1 pre-dose, 2, 4, 6, 8, 12, 24h post-dose, Day 4 pre-dose, Day 6 pre-dose, Day 7 pre-dose, 2, 4, 6, 8, 12, 24, 48h post-dose
Plan to share: No
No publications or documents are linked to this record.
Ran from Dec 2017 to primary completion in Nov 2018, 11 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Jeil Pharmaceutical Co., Ltd. →